Skip to main content
Premium Trial:

Request an Annual Quote

Trovagene to Offer Liquid Biopsy Through America's Choice Provider Network

NEW YORK (GenomeWeb) – Trovagene announced today that it has signed an agreement to offer its circulating tumor DNA Precision Cancer Monitoring tests and services through America's Choice Provider Network (ACPN).

Under the terms of the deal, Trovagene has become a preferred provider for the network and its liquid biopsy testing services will be covered by more than 1,700 payors in North America and available under in-network coverage to 22 million individuals.

"We are pleased that ACPN has agreed to provide coverage for Trovagene's PCM full offering of ctDNA products," Matt Posard, chief commercial officer of Trovagene, said in a statement. "Our commercial plan is on track to provide national sales coverage, and ACPN is the first of several additional contracts expected this year." 

Additional terms of the arrangement were not disclosed.